Reviewed assessment
Where this organization could contribute.
Follow the reviewed Mission area and Defence need connections to understand the problem this organization may help address, the public evidence behind the assessment, and what to verify before engagement.
Mission areas
Contributing capability
Universal blood-type conversion platform
Edge Data Processing
A portable, workflow-compatible clinical technology for urgent or remote care could be relevant to distributed support contexts; this is a derived assessment and is not a public procurement claim.
Evidence strength: Needs ReviewCapability last reviewed Aug 5, 2026
Open Mission areaReviewed connections indicate possible relevance based on public evidence. They do not indicate procurement direction, eligibility, endorsement or customer interest.
Technologies and services
A closer look at the products, services, operating features, and documented applications that shape the organization’s role.
Preclinical enzyme-enabled blood and organ compatibility platform
Universal blood-type conversion platform
What it enables
Use paired bacterial enzymes during ex vivo machine perfusion to remove type-A antigens from donor kidneys and other blood-group-bearing tissues. Peer-reviewed studies report approximately 80% kidney A-antigen removal within two hours and no hyperacute rejection in a preclinical human-decedent transplant model, while also recording antigen regeneration and later immune-mediated signs that remain unresolved for clinical use.
Public record
Public programs and contracts
Dated participation, delivery roles, partnerships, and disclosed funding provide the operating context behind the profile.
Ecosystem relationships
2026 cohort participant
NATO DIANA
Avivo's public media page reports selection to NATO DIANA's 2026 innovator cohort; the candidate records program participation only and does not infer a military customer or medical authorization.
Prepare the conversation
Questions for a first conversation
Which Universal blood-type conversion platform configurations are commercially available now, what integration or qualification work is required, and which public customer or deployment evidence can be shared?
Avivo Biomedical's public evidence establishes its current role and offering, but it does not answer every access, configuration, eligibility, maturity or buyer question needed for a first business-development conversation.
Geography
Vancouver, British Columbia
The map is centred on Vancouver. It does not imply a street address or exact facility location.
Open in the ecosystem mapSource library
Sources behind this profile
Open the original record, then expand the source details to see which parts of the dossier it informs.
Public sources cited · Facts and assessments kept separate · Human review
Public sources
5
Last reviewed
Aug 11, 2026
Identity and profile
- Open source: Avivo company and technology profile (opens in a new tab)
Avivo company and technology profile
Avivo Biomedical
Source details
Move into a better-informed conversation
Take this dossier into the next conversation.
Save the organization and its public record in a private Shortlist, then request a human-routed introduction when the fit is specific enough to discuss.